Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination

Prathit A. Kulkarni; Vinay Prasad

doi:10.1007/s11684-021-0895-9

Front. Med. ›› 2021, Vol. 15 ›› Issue (6) : 938 -941. DOI: 10.1007/s11684-021-0895-9

COMMENT

Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination

Prathit A. Kulkarni ¹^,²^,^†
, Vinay Prasad ³

Author information +

History +

PDF (72KB)

Cite this article

Download citation ▾

Prathit A. Kulkarni, Vinay Prasad. Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Front. Med., 2021, 15(6): 938-941 DOI:10.1007/s11684-021-0895-9

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	U.S. Centers for Disease Control & Prevention. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. Press release on April 13, 2021. 2021. accessed April 24, 2021)

[2]	U.S. Centers for Disease Control & Prevention. Health Alert Network Advisory on April 13, 2021. 2021. accessed April 24, 2021)

[3]	U.S. Centers for Disease Control & Prevention. ACIP presentation slides: May 12, 2021 meeting. 2021. accessed August 2, 2021)

[4]

Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(4): 1158–1192

[5]

Sánchez van Kammen M, Heldner MR, Brodard J, Scutelnic A, Silvis S, Schroeder V, Kremer Hovinga JA, Middeldorp S, Levi M, Hiltunen S, Lindgren E, Mansour M, Arauz A, Barboza MA, Zuurbier SM, Aguiar de Sousa D, Ferro JM, Fischer U, Field TS, Jood K, Tatlisumak T, Putaala J, Arnold M, Coutinho JM. Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. JAMA 2021; 326(4): 332–338

[6]	U.S. Centers for Disease Control & Prevention. ACIP presentation slides: April 23, 2021 meeting. 2021. accessed April 24, 2021)

[7]

See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021; 325(24): 2448–2456

[8]	Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384(22): 2092–2101

[9]	Schultz NH, Sárvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384(22): 2124–2130

[10]	Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19. N Engl J Med 2021; 384(23): 2202–2211

[11]	Vayne C, Rollin J, Gruel Y, Pouplard C, Galinat H, Huet O, Mémier V, Geeraerts T, Marlu R, Pernod G, Mourey G, Fournel A, Cordonnier C, Susen S. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385(4): 376–378

[12]	U.S. Centers for Disease Control & Prevention. ACIP presentation slides: July 22, 2021 meeting. 2021. accessed August 2, 2021)

[13]	United Kingdom Joint Committee on Vaccination and Immunisation. Use of the AstraZeneca COVID-19 (AZD1222) vaccine: Updated JCVI statement, 7 May 2021. 2021. accessed August 2, 2021)